News

Vonaprument, formerly known as ANX007, is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. It has secured Priority

This acquisition expands Intas and Accord’s biosimilar portfolio approved by the FDA and expedites their growth in the global market. With the acquisition, Intas’ US speciality business Accord

CTx-1301 is an extended-release tablet formulation designed for fast onset, all-day efficacy, and a smooth pharmacokinetic profile with a single dose. Cingulate anticipates learning whether the NDA has

The approved drug is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and above, as well as children between six to

The new facility will help Minaris support its worldwide cell and gene therapy growth. It is designed to facilitate the technology transfer of commercial advanced therapies into Europe.

Turbine noted that laboratory models often fail to capture the molecular diversity and biological complexity of many solid tumours found in patients. This limitation hampers the development of

VT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor to target the Hippo pathway by inhibiting the palmitoylation of TEAD protein family members. Vivace Therapeutics president and

This collaboration is said to result in a “scalable” cGMP production process for DTx’s AAV-based gene therapy candidate targeting open angle glaucoma. As part of this partnership, Northway

This designation is granted for treatments that could significantly improve upon existing options. The FDA’s decision is expected by the fourth quarter of 2025, in line with the